New Results
A drug candidate for treating adverse reactions caused by pathogenic antibodies inducible by COVID-19 virus and vaccines
View ORCID ProfileHuiru Wang, Xiancong Wu, Yuekai Zhang, Qiuchi Chen, Lin Dai, Yuxing Chen, Xiaoling Liu
doi: https://doi.org/10.1101/2021.07.13.452194
Huiru Wang
1Huirui Biopharma, Co., Ltd. Hangzhou, China
Xiancong Wu
2HuaAn McAb Biotechnology, Co., Ltd. Hangzhou, China
Yuekai Zhang
3Biolynx Technology (Hangzhou), Co., Ltd. Hangzhou, China
Qiuchi Chen
2HuaAn McAb Biotechnology, Co., Ltd. Hangzhou, China
Lin Dai
2HuaAn McAb Biotechnology, Co., Ltd. Hangzhou, China
Yuxing Chen
2HuaAn McAb Biotechnology, Co., Ltd. Hangzhou, China
Xiaoling Liu
2HuaAn McAb Biotechnology, Co., Ltd. Hangzhou, China
Article usage
Posted July 13, 2021.
A drug candidate for treating adverse reactions caused by pathogenic antibodies inducible by COVID-19 virus and vaccines
Huiru Wang, Xiancong Wu, Yuekai Zhang, Qiuchi Chen, Lin Dai, Yuxing Chen, Xiaoling Liu
bioRxiv 2021.07.13.452194; doi: https://doi.org/10.1101/2021.07.13.452194
Subject Area
Subject Areas
- Biochemistry (11752)
- Bioengineering (8752)
- Bioinformatics (29200)
- Biophysics (14974)
- Cancer Biology (12096)
- Cell Biology (17411)
- Clinical Trials (138)
- Developmental Biology (9421)
- Ecology (14182)
- Epidemiology (2067)
- Evolutionary Biology (18308)
- Genetics (12245)
- Genomics (16803)
- Immunology (11869)
- Microbiology (28097)
- Molecular Biology (11594)
- Neuroscience (60969)
- Paleontology (451)
- Pathology (1871)
- Pharmacology and Toxicology (3238)
- Physiology (4959)
- Plant Biology (10427)
- Synthetic Biology (2886)
- Systems Biology (7340)
- Zoology (1651)